Patient Case: Reducing The Risk for Adverse Events in a T2DM Patient with HFrEF, CKD, and Existing ASCVD
The advent of SGLT-2 inhibitors and GLP-1 RAs to address cardiorenal risk in patients with and without type 2 diabetes, has opened up new avenues of prevention and treatment. However, individualizing the vast amount of evidence to patient care remains challenging. During this case, you will have a chance to explore treatment decisions to decrease overall cardiorenal risk in a complex patient, accompanied by expert commentary and brief review of evidence with SGLT-2is and GLP-1 RAs across cardiovascular outcomes trials.
This activity is designed for US-based healthcare professionals, including cardiologists, endocrinologists, primary care clinicians (PCPs), nurse practioners, nurses, pharmacists, and other allied health professionals.
After completing this activity, the participant should be better able to:
- Summarize updated guidelines and recently-concluded studies about the efficacy and safety of SGLT-2is and GLP-1 RAs in addressing cardio-renal risk in patients with and without T2D.
- Develop individualized treatment regimens based on the latest evidence and guideline recommendations to address cardio-renal risk in patients with T2D.
Robert H. Eckel, MD
Professor of Medicine, Emeritus
Division of Endocrinology, Metabolism and Diabetes
Division of Cardiology
University of Colorado Anschutz Medical Campus
Past President, American Heart Association
President, Medicine and Science, American Diabetes Association
Dr. Eckel discloses the following:
Consulting Fees: Sanofi/Regeneron, Novo Nordisk
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
This activity is supported by an educational grant from AstraZeneca.
JOINTLY PROVIDED BY
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Cardiometabolic Health Congress. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
AMA PRA Category 1 CreditTM Designation Statement
The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
1.0 contact hours may be earned for successful completion of this activity.
The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This program is assigned ACPE Universal Activity #0797-9999-21-099-H01-P. This program is designated for up to 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit.
Type of Activity: Knowledge
Upon completing the post-survey and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Dietician Continuing Education
This program offers 1.0 CPEUs for dieticians.
ACCREDITED PROVIDER DISCLOSURE
Annenberg Center for the Health Sciences at Eisenhower staff involved in this activity have no relevant commercial relationships to disclose.
The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.
CONFLICT OF INTEREST DISCLOSURE POLICY
Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to Annenberg Center for Health Sciences at Eisenhower policy. Annenberg Center for Health Sciences at Eisenhower is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ACCME-defined ineligible company.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period June 22, 2021 through June 22, 2022, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.annenberg.net.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 CDE
- 1.00 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.